Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
- Revenue in USD (TTM)81.51k
- Net income in USD-29.11m
- Incorporated1987
- Employees--
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY NSW 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solid Biosciences Inc | 0.00 | -90.69m | 308.76m | 88.00 | -- | 1.60 | -- | -- | -3.30 | -3.30 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -41.63 | -49.99 | -44.77 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0076 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 310.03m | 168.00 | -- | 0.8104 | -- | 7.64 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
ADC Therapeutics SA | 66.75m | -214.86m | 310.24m | 273.00 | -- | -- | -- | 4.65 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
Biomea Fusion Inc | 0.00 | -139.65m | 315.39m | 112.00 | -- | 3.03 | -- | -- | -3.90 | -3.90 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -72.58 | -- | -80.88 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
enGene Holdings Inc | 0.00 | -123.44m | 316.58m | 33.00 | -- | 1.37 | -- | -- | -4.77 | -4.77 | 0.00 | 5.21 | 0.00 | -- | -- | 0.00 | -78.13 | -- | -84.20 | -- | -- | -- | -- | -- | -- | -3.14 | 0.0906 | -- | -- | -- | -260.87 | -- | -- | -- |
Sutro Biopharma Inc | 169.36m | -124.45m | 321.30m | 304.00 | -- | 2.11 | -- | 1.90 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
Editas Medicine Inc | 67.03m | -193.45m | 322.48m | 265.00 | -- | 1.39 | -- | 4.81 | -2.36 | -2.36 | 0.8183 | 2.81 | 0.1447 | -- | 52.99 | 252,954.70 | -41.75 | -29.85 | -48.49 | -33.19 | -- | -- | -288.59 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Atea Pharmaceuticals Inc | 0.00 | -176.00m | 322.49m | 75.00 | -- | 0.6768 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
Ocugen Inc | 8.19m | -45.87m | 328.16m | 65.00 | -- | 17.34 | -- | 40.06 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Immutep Ltd - ADR | 81.51k | -29.11m | 329.11m | -- | -- | 2.55 | -- | 4,037.66 | -0.2402 | -0.2402 | 0.0007 | 0.8808 | 0.0007 | -- | 0.655 | -- | -24.48 | -- | -25.99 | -- | -- | -- | -35,710.27 | -- | -- | -- | 0.0083 | -- | -37.61 | -- | -7.07 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -50.53m | 331.80m | 57.00 | -- | 1.27 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Personalis Inc | 80.03m | -81.45m | 336.21m | 223.00 | -- | 2.80 | -- | 4.20 | -1.63 | -1.63 | 1.59 | 2.12 | 0.3683 | 6.68 | 6.94 | 358,865.50 | -37.49 | -28.84 | -43.81 | -34.72 | 27.76 | 28.65 | -101.78 | -96.01 | 3.05 | -- | 0.0199 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
MeiraGTx Holdings PLC | 8.12m | -93.14m | 336.52m | 387.00 | -- | 3.52 | -- | 41.43 | -1.49 | -1.49 | 0.1298 | 1.24 | 0.0282 | -- | 0.4733 | 19,384.25 | -32.29 | -26.40 | -40.66 | -32.66 | -- | -- | -1,146.81 | -420.70 | -- | -22.76 | 0.4759 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
Lexeo Therapeutics Inc | 0.00 | -77.22m | 344.50m | 58.00 | -- | 2.09 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Voyager Therapeutics Inc | 143.77m | 9.02m | 344.65m | 162.00 | 41.19 | 1.03 | 24.81 | 2.40 | 0.1534 | 0.1534 | 2.75 | 6.16 | 0.3825 | -- | 43.56 | 887,462.90 | 2.40 | 0.6378 | 2.71 | 0.8203 | -- | -- | 6.28 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
XOMA Royalty Corp | 15.24m | -25.10m | 349.38m | 13.00 | -- | 3.48 | -- | 22.93 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
Holder | Shares | % Held |
---|---|---|
Pengana Capital Ltd.as of 31 May 2024 | 970.61k | 0.67% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 839.08k | 0.58% |
Meridian Wealth Management LLCas of 30 Jun 2024 | 381.20k | 0.26% |
Susquehanna Financial Group LLLPas of 30 Jun 2024 | 248.12k | 0.17% |
Jane Street Capital LLCas of 30 Jun 2024 | 125.58k | 0.09% |
Old Mission Capital LLCas of 30 Jun 2024 | 113.04k | 0.08% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 100.30k | 0.07% |
Citadel Securities LLCas of 30 Jun 2024 | 96.80k | 0.07% |
Millennium Management LLCas of 30 Jun 2024 | 71.21k | 0.05% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 66.44k | 0.05% |